Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Merck's Dificid for Infections in Children

By Brian Orelli, PhD - Jan 27, 2020 at 7:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The approval includes a new oral suspension version of the drug.

The U.S. Food and Drug Administration approved Merck's (MRK -0.29%) Dificid drug for children aged 6 months and older who have diarrhea caused by a specific bacterial infection called Clostridioides difficile (C. diff).

A tablet form of the drug was already approved for adults with diarrhea caused by the bacteria. In addition to expanding the approval for the tablet form to children, the FDA also approved an oral suspension of the drug that will be easier for children to take than the tablet.

Doctor using a stethoscope on a young boy.

Image source: Getty Images.

Dificid isn't absorbed by the body, making it effective at treating infections of the gut that cause diarrhea, but ineffective at treating bacterial infections in other parts of the body. C. diff causes almost 500,000 infections annually in the U.S., with about 29,000 of those patients dying within 30 days of initial diagnosis.

The drug seems to work as well as vancomycin, which is available as a generic, but appears to have a lower recurrence rate. In a clinical trial run by Merck's collaborator Astellas Pharma, Dificid eradicated the bacteria as well as vancomycin when measured two days after the 10-day treatment. Looking further out, at 30 days, 68.4% of the children taking Dificid were cured of their infection that didn't return, compared to just 50% of children taking vancomycin.

Merck and Astellas ended up owning rights to the same drug through a series of acquisitions and licensing deals. Merck gained access to Dificid through its 2015 acquisition of Cubist Pharmaceuticals, which had acquired the drug's original developer, Optimer Pharmaceuticals. Before that, Astellas had licensed rights from Optimer to sell the drug in Japan and Europe, where it's marketed as Dificlir.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$88.93 (-0.29%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.